My Locations
Part of the Duke Cancer Institute
Part of the Duke Cancer Institute
About Me
I entered medical school for the sole purpose of learning more about human diseases, so that I could focus my laboratory efforts on improving the human condition. However, I was surprised to find myself drawn to clinical care. I care for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, I have had the privilege of treating people facing life-threatening illnesses. I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions. I engage in clinical research, evaluating novel agents that directly target the cancer cell to improve the degree of success in treating this illness. My patients benefit from my understanding of the newest available treatments, and also have access to promising investigational agents, when appropriate. In my faculty position at Duke University, I enjoy educating current oncologists as well as the next generation of physicians.
- Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy 2023
- Member of the Duke Cancer Institute, Duke Cancer Institute 2018
Call for an Appointment
Areas of Expertise
- Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Hairy Cell Leukemia
- Myelodysplastic Syndrome
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Myeloproliferative Neoplasms
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
In the News
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Clinical Focus and Research
I treat people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). In general, therapies initially developed for these cancers were drugs that killed cells that are dividing. Unfortunately, many normal cells in the body are also affected or killed by these drugs as well, leading to the unwanted toxicities of chemotherapy. Over the years, we have gained tremendous insight into the specific events that cause a cell to become cancerous and have developed better tools for distinguishing normal from cancerous cells. My clinical research effort for over 20 years has focused on the development of drugs that specifically target the abnormalities of the leukemia cell. I study the effects associated with treating people with investigational agents that target the molecular changes that are specific to blood cancers. I have been an active member of teams of doctors that have brought new treatments to people with leukemia, such as oral drugs that inactivate FLT3 and IDH. In this way we hope to improve the outcome of people with blood cancers with fewer unwanted side effects.
-
DSP: Phase 1/2 DSP-5336 in Acute LeukemiaIRB# PRO00109316 , NCT# NCT04988555
-
S1905 T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)IRB# PRO00112400 , NCT# NCT04315324
-
EA9181 (Acute Lymphoblastic Leukemia)IRB# PRO00108100 , NCT# NCT04530565
-
MyeloMATCH MSRP (Acute Myeloid Leukemia & Myelodysplastic Syndrome)IRB# PRO00116097 , NCT# NCT05564390
-
MyeloMATCH MM1YA-S01 (Acute Myeloid Leukemia)IRB# PRO00116098 , NCT# NCT05554406
-
MyeloMATCH MM1OA-EA02 (Acute Myeloid Leukemia)IRB# PRO00116258 , NCT# NCT06317649
-
Kura :A Study of the Safety and Tolerability of Ziftomenib (Acute Myeloid Leukemia)IRB# PRO00113005 , NCT# NCT05735184
-
The FRIDA Study (Relapsed or Refractory Acute Myeloid Leukemia)IRB# PRO00113157 , NCT# NCT05546580
-
MacroGenics: Bispecific DART in R/R Heme Malignancies (Blood & Bone Marrow Cancers)IRB# PRO00110825 , NCT# NCT05362773
-
MyeloMATCH MM1YA-CTG01 (Acute Myeloid Leukemia)IRB# PRO00116800 , NCT# NCT05554393
- CL04-ORY-1001 awarded by Oryzon Genomics SA 2023 - 2028
- Pratz, Keith W., and Harry P. Erba. “Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents.” Am J Hematol 100 Suppl 2 (March 2025): 16–22. https://doi.org/10.1002/ajh.27585.
- Othus, Megan, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, Eliana Dietrich, Suravi Raychaudhuri, Jacob Appelbaum, Elihu Estey, and Mary-Elizabeth Percival. “Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.” Leukemia 39, no. 3 (March 2025): 752–54. https://doi.org/10.1038/s41375-024-02512-3.
- Erba, Harry P. “A study to learn how well quizartinib with chemotherapy works and how safe it is in people with acute myeloid leukemia that is FLT3-ITD-positive: a plain language summary of the QuANTUM-First study.” Future Oncol 21, no. 5 (February 2025): 533–47. https://doi.org/10.1080/14796694.2024.2422261.
- Erba, H. P. “Clinical Manifestations and Treatment of Acute Myeloid Leukemia.” In Hematology: Basic Principles and Practice, Eighth Edition, 950–76, 2022. https://doi.org/10.1016/B978-0-323-73388-5.00060-2.
- Borate, U., and H. P. Erba. “Cytogenetics and Prognostic Models in Myelodysplastic Syndromes.” In Cancer Consult: Expertise for Clinical Practice, 106–12, 2014. https://doi.org/10.1002/9781118589199.ch15.
- DiNardo, Courtney D., Gail J. Roboz, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” In Clinical Lymphoma Myeloma and Leukemia, 19:S220–S220. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.07.094.
- Roboz, Gail J., Courtney Denton Dinardo, Eytan M. Stein, Stephane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, et al. “Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
- DeAngelo, Daniel J., Harry Paul Erba, Brian Andrew Jonas, Michael O’Dwyer, Paula Marlton, Gerwin A. Huls, Jane Liesveld, et al. “A phase Ill trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- AbbVie, Inc.
- Bristol-Myers Squibb
- Daiichi Sankyo Co., Ltd
- Glycomimetics
- Incyte
- Jazz Pharmaceuticals
- Kura Oncology
- Servier
- Sumitomo Dainippon Pharma Oncology
- Syndax
- Thermo Fischer